BioMarin PharmaceuticalsBMRN
About: BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Employees: 3,401
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
75% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]
1.83% more ownership
Funds ownership: 94.32% [Q3] → 96.15% (+1.83%) [Q4]
10% more call options, than puts
Call options by funds: $141M | Put options by funds: $128M
9% more repeat investments, than reductions
Existing positions increased: 198 | Existing positions reduced: 182
5% less capital invested
Capital invested by funds: $12.6B [Q3] → $12B (-$573M) [Q4]
5% less first-time investments, than exits
New positions opened: 86 | Existing positions closed: 91
3% less funds holding
Funds holding: 544 [Q3] → 527 (-17) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Oppenheimer Leland Gershell 38% 1-year accuracy 21 / 55 met price target | 41%upside $98 | Outperform Upgraded | 24 Feb 2025 |
Scotiabank George Farmer 25% 1-year accuracy 5 / 20 met price target | 15%upside $80 | Sector Perform Maintained | 20 Feb 2025 |
Citigroup David Lebovitz 67% 1-year accuracy 10 / 15 met price target | 18%upside $82 | Neutral Maintained | 20 Feb 2025 |
RBC Capital Luca Issi 17% 1-year accuracy 9 / 52 met price target | 1%upside $70 | Sector Perform Reiterated | 20 Feb 2025 |
Cantor Fitzgerald Olivia Brayer 53% 1-year accuracy 10 / 19 met price target | 30%upside $90 | Overweight Reiterated | 20 Feb 2025 |
Financial journalist opinion
Based on 23 articles about BMRN published over the past 30 days
